Deucravacitinib in moderate-to-severe plaque psoriasis: Pooled safety and tolerability over 52 weeks from two phase 3 trials (POETYK PSO-1 and PSO-2)

By sjmartinez • March 8, 2024

Strober B, Blauvelt A, Warren RB, Papp KA, Armstrong AW, Gordon KB, Morita A, Alexis AF, Lebwohl M, Foley P, Kisa RM, Colston E, Wang T, Banerjee S, Thaçi D. Deucravacitinib in moderate-to-severe plaque psoriasis: Pooled safety and tolerability over 52 weeks from two phase 3 trials (POETYK PSO-1 and PSO-2). J Eur Acad Dermatol Venereol. 2024 Mar 7. doi: 10.1111/jdv.19925. Epub ahead of print. PMID: 38451052.

Tags: Dermatology, Publications

Retraction Note: sFRP2 in the aged microenvironment drives melanoma metastasis and therapy resistance

Kaur A, Webster MR, Marchbank K, Behera R, Ndoye A, Kugel CH 3rd, Dang VM, Appleton J, O'Connell MP, Cheng P, Valiga AA, Morissette R,[...]

Exacerbation of bullous systemic lupus erythematosus with erythema gyratum repens-like pattern following dupilumab

Santiago Mangual KP, Truong A, Mo J, Liu J, Khaligi MA, Haussmann A, Razmjou AA, Holland V, Cheng K. Exacerbation of bullous systemic lupus erythematosus[...]

Chronic companions: An updated national cross-sectional study of metabolic syndrome comorbidities in outpatient visits for hidradenitis suppurativa

Ma EJ, Roberts AM, Chou P, Katz A, Jeong CY, Nong Y, Ochoa MT, Armstrong AW. Chronic companions: An updated national cross-sectional study of metabolic[...]